The following information is disclosed in accordance with Rule 26 of the AIM Rules (January 2021). These requirements were last reviewed and updated by the Company on 25 January 2023.
| Description of Business | Redx Pharma plc was formed in 2010 and is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted medicines for the treatment of cancer and fibrotic disease and the emerging area of cancer-associated fibrosis. The Company’s accomplishments are evidenced not only by its two wholly-owned clinical-stage product candidates and rapidly expanding pipeline, but also by its strategic transactions. | ||||||
| Incorporation & Registered Office | Redx Pharma plc is registered in England & Wales number 07368089 Block 33, Mereside, Alderley Park, Macclesfield, SK10 4TG, UK |
||||||
| Directors | Dr Jane Griffiths (Chair) Lisa Anson (CEO) Peter Presland (Non-Executive Director) Dr Bernhard Kirschbaum (Non-Executive Director) Sarah Gordon Wild (Non-Executive Director) Dr Thomas Burt (Non-Executive Director) Natalie Berner (Non-Executive Director) Dr Rob Scott (Non-Executive Director) View Directors’ biographies |
||||||
| Advisors | Nominated Advisor SPARK Advisory Partners Limited 5 St. John’s Lane London EC1M 4BH, UK Joint Broker WG Partners LLP 85 Gresham Street London EC2V 7NQ, UK Joint Broker Panmure Gordon (UK) Limited One New Change London EC4M 9AF, UK Auditor Ernst & Young LLP One Cambridge Business Park Cowley Road Cambridge CB4 0WZ, UK Financial Communications Advisor FTI Consulting 200 Aldersgate Street London EC1A 4HD, UK | Legal Advisor Cooley (UK) LLP 22 Bishopsgate London EC2N 4BQ, UK Registrar Equiniti Limited Aspect House Spencer Road Lancing West Sussex BN99 6DA, UK |
|||||
| Corporate Governance | The Board seeks to follow best practice in corporate governance appropriate with the size and regulatory framework that applies to AIM companies. The Board reviews and applies the principles and provisions of the 2018 Quoted Company Alliance Corporate Governance Code (“Code”) where it is appropriate to do so to support the governance framework. The main features of the Group’s corporate governance arrangements are:
| Audit, Risk and Disclosure Committee Peter Presland (C), Sarah Gordon Wild and Rob Scott Committee terms of reference PDF Remuneration Committee Sarah Gordon Wild (C), Peter Presland and Bernhard Kirschbaum Committee terms of reference PDF Science Committee Bernhard Kirschbaum (C), Rob Scott and Lisa Anson Committee terms of reference PDF |
|||||
| Constitutional Documents | Articles of Association PDF | ||||||
| Exchanges & Trading Platforms | The Company is not listed on any other Exchanges or Trading Platforms. | ||||||
| Shares & Significant Shareholders | Total number of shares issued: 334,911,458 Number of shares (if any) held in treasury: Nil Shareholders with >3% of total issued: |
||||||
| Name | Number of shares | Percentage of issued shares | |||||
| Funds Managed by Redmile Group, LLC | 245,341,627 | 73.26% | |||||
| Sofinnova Crossover I SLP | 44,061,134 | 13.16% | |||||
| Polar Capital | 16,434,331 | 4.91% | |||||
| Last updated 25/01/2023 | |||||||
| Shares Not in Public Hands | Pursuant to the AIM Rules, and insofar as the Company is aware, as at 25/01/2023, 86.92% of the Company’s AIM securities were not in public hands. | ||||||
| Share Restrictions | There are no restrictions on the transfer of securities. | ||||||
| Admission Document | Company admission document PDF | ||||||
| Shareholder Circulars | Click to view Shareholder Circulars | ||||||
| Takeover Code | The Company is subject to the UK City Code on Takeovers and Mergers. | ||||||
| Latest Annual Report | Click to view the latest annual report | ||||||
| RNS Announcements | Click to view the company’s RNS Announcements | ||||||